DongKook Pharmaceutical Co. Ltd - Asset Resilience Ratio
DongKook Pharmaceutical Co. Ltd (086450) has an Asset Resilience Ratio of 5.47% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check DongKook Pharmaceutical Co. Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how DongKook Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. See debt-free asset ratio of DongKook Pharmaceutical Co. Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down DongKook Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DongKook Pharmaceutical Co. Ltd (086450) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩59.67 Billion | 5.47% |
| Total Liquid Assets | ₩59.67 Billion | 5.47% |
Asset Resilience Insights
- Limited Liquidity: DongKook Pharmaceutical Co. Ltd maintains only 5.47% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
DongKook Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio
Compare DongKook Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 65.38% |
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
|
Kolon Life Science Inc
KQ:102940 |
Pharmaceuticals | 1.22% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 13.09% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
Annual Asset Resilience Ratio for DongKook Pharmaceutical Co. Ltd (2013–2025)
The table below shows the annual Asset Resilience Ratio data for DongKook Pharmaceutical Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.67% | ₩70.92 Billion ≈ $48.06 Million |
₩1.06 Trillion ≈ $720.31 Million |
-2.86pp |
| 2024-12-31 | 9.53% | ₩90.85 Billion ≈ $61.57 Million |
₩953.16 Billion ≈ $645.95 Million |
-1.68pp |
| 2023-12-31 | 11.22% | ₩94.16 Billion ≈ $63.81 Million |
₩839.54 Billion ≈ $568.94 Million |
-2.31pp |
| 2022-12-31 | 13.53% | ₩103.95 Billion ≈ $70.45 Million |
₩768.33 Billion ≈ $520.69 Million |
-8.99pp |
| 2021-12-31 | 22.52% | ₩168.93 Billion ≈ $114.48 Million |
₩750.08 Billion ≈ $508.32 Million |
-3.74pp |
| 2020-12-31 | 26.27% | ₩174.19 Billion ≈ $118.04 Million |
₩663.17 Billion ≈ $449.42 Million |
-1.82pp |
| 2019-12-31 | 28.09% | ₩152.89 Billion ≈ $103.61 Million |
₩544.38 Billion ≈ $368.92 Million |
+3.88pp |
| 2018-12-31 | 24.21% | ₩116.26 Billion ≈ $78.78 Million |
₩480.24 Billion ≈ $325.45 Million |
-3.67pp |
| 2017-12-31 | 27.88% | ₩104.08 Billion ≈ $70.54 Million |
₩373.31 Billion ≈ $252.99 Million |
+0.31pp |
| 2016-12-31 | 27.57% | ₩89.62 Billion ≈ $60.74 Million |
₩325.10 Billion ≈ $220.31 Million |
+18.06pp |
| 2015-12-31 | 9.51% | ₩26.12 Billion ≈ $17.70 Million |
₩274.80 Billion ≈ $186.23 Million |
-0.47pp |
| 2014-12-31 | 9.98% | ₩24.36 Billion ≈ $16.51 Million |
₩244.17 Billion ≈ $165.47 Million |
-1.19pp |
| 2013-12-31 | 11.17% | ₩24.37 Billion ≈ $16.51 Million |
₩218.26 Billion ≈ $147.91 Million |
-- |
About DongKook Pharmaceutical Co. Ltd
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durak… Read more